Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Oncogene ; 36(43): 6049-6058, 2017 10 26.
Article in English | MEDLINE | ID: mdl-28759044

ABSTRACT

Glioblastomas represent the most aggressive glioma grade and are associated with a poor patient prognosis. The current standard of care, consisting of surgery, radiation and chemotherapy, only results in a median survival of 14 months, underscoring the importance of developing effective new therapeutic strategies. Among the challenges in treating glioblastomas are primary resistance and the rapid emergence of recurrent disease, which can result from tumor cell-intrinsic mechanisms in addition to tumor microenvironment (TME)-mediated extrinsic resistance. Using a PDGF-B-driven proneural glioma mouse model, we assessed a panel of tyrosine kinase inhibitors with different selectivity profiles. We found that PLX3397, an inhibitor of colony stimulating factor-1 receptor (CSF-1R), blocks glioma progression, markedly suppresses tumor cell proliferation and reduces tumor grade. By contrast, the multi-targeted tyrosine kinase inhibitors dovitinib and vatalanib, which directly target tumor cells, exert minimal anti-tumoral effects in vivo, despite killing glioma cells in vitro, suggesting a TME-mediated resistance mechanism may be involved. Interestingly, PLX3397 interferes with tumor-mediated education of macrophages and consequently restores the sensitivity of glioma cells to tyrosine kinase inhibitors in vivo in preclinical combination trials. Our findings thus demonstrate that microenvironmental alteration by CSF-1R blockade renders tumor cells more susceptible to receptor tyrosine kinase inhibition in a preclinical glioblastoma model, which may have important translational relevance.


Subject(s)
Drug Resistance, Neoplasm/genetics , Glioma/drug therapy , Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Aminopyridines/administration & dosage , Animals , Becaplermin , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , Glioma/genetics , Glioma/pathology , Humans , Mice , Protein Kinase Inhibitors/administration & dosage , Proto-Oncogene Proteins c-sis/genetics , Pyrroles/administration & dosage , Tumor Microenvironment/drug effects
2.
Oncogene ; 33(14): 1799-808, 2014 Apr 03.
Article in English | MEDLINE | ID: mdl-23644656

ABSTRACT

Heparan sulfate proteoglycans are an important and abundant component of the extracellular matrix, which undergo substantial remodeling throughout tumorigenesis via the enzymatic activity of heparanase. Heparanase has been shown to be upregulated in many human cancers; however, its specific functions in human pancreatic neuroendocrine tumors (PanNETs) and spontaneous mouse models of cancer have not been evaluated. Here, we investigated the role of heparanase in PanNETs using patient samples and the RIP1-Tag2 (RT2) PanNET-transgenic mouse model. High heparanase expression significantly correlated with more advanced tumor stage, higher tumor grade and the presence of distant metastasis in PanNET patients. We genetically manipulated heparanase levels in the RT2 model using heparanase-transgenic mice, which constitutively overexpress heparanase, and heparanase-knockout mice. Heparanase was found to have a critical role in promoting tumor invasion, through both macrophage and cancer cell sources in the tumor microenvironment. In addition, elevated heparanase levels significantly increased peritumoral lymphangiogenesis in vivo and promoted the trans-differentiation of macrophages into lymphatic endothelial cell-like structures in culture. Conversely, we found that heparanase deletion led to increased angiogenesis and pericyte coverage. Together, these data identify important roles for heparanase in regulating several critical aspects of tumorigenesis, demonstrating that heparanase represents a potential therapeutic target for PanNET patients.


Subject(s)
Glucuronidase/metabolism , Lymphangiogenesis/genetics , Neuroendocrine Tumors/enzymology , Pancreatic Neoplasms/enzymology , Animals , Disease Progression , Female , Flow Cytometry , GTPase-Activating Proteins/metabolism , Glucuronidase/genetics , Heparan Sulfate Proteoglycans/chemistry , Humans , Immunohistochemistry , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neoplasm Invasiveness , Neovascularization, Pathologic , Neuroendocrine Tumors/pathology , Pancreatic Neoplasms/pathology
3.
Oncogene ; 31(11): 1459-67, 2012 Mar 15.
Article in English | MEDLINE | ID: mdl-21822305

ABSTRACT

Tumor-associated macrophages have recently emerged as a key regulatory cell type during cancer progression, and have been found to promote tumor malignancy in the majority of studies performed to date. We show in this study that CD68(+) macrophages positively correlate with tumor grade and liver metastasis in human pancreatic neuroendocrine tumors (PNETs). To investigate the potential mechanisms whereby macrophages can promote PNET progression, we crossed the RIP1-Tag2 (RT2) mouse model of pancreatic islet cancer to colony-stimulating factor-1 (CSF-1)-deficient Csf1(op/op) mice, which have reduced numbers of tissue macrophages. Csf1(op/op) RT2 mice had a substantial reduction in cumulative tumor burden, which interestingly resulted from a significant decrease in angiogenic switching and tumor number, rather than an evident effect on tumor growth. In the tumors that did develop in CSF-1-deficient animals, however, there were no significant differences in tumor cell proliferation, apoptosis, angiogenesis or invasion. CSF-1 deficiency decreased macrophage infiltration by approximately 50% during all stages of RT2 tumor progression. Interestingly, several cytokines were upregulated in CSF-1-deficient RT2 tumors, and neutrophil infiltration was increased. These results show that macrophages are important for promoting PNET development and suggest that additional factors contribute to the recruitment and survival of myeloid cells in RT2 tumors in the absence of CSF-1.


Subject(s)
Macrophage Colony-Stimulating Factor/deficiency , Macrophages/metabolism , Neuroendocrine Tumors/genetics , Pancreatic Neoplasms/genetics , Adenoma, Islet Cell/genetics , Adenoma, Islet Cell/pathology , Animals , Humans , Mice , Mice, Transgenic , Pancreatic Neoplasms/pathology
4.
Vet Ther ; 7(1): 15-26, 2006.
Article in English | MEDLINE | ID: mdl-16598680

ABSTRACT

A new antimicrobial ear cleanser was evaluated for the treatment of bacterial and yeast ear infection in dogs. Forty-five dogs with erythemato-ceruminous or purulent otitis externa were randomly allocated to two treatment groups: reference ear cleanser (Epiotic, Virbac) or test ear cleanser (Epiotic Advanced, Virbac). Ear cleansing was performed twice daily for 2 weeks, and no other treatment was allowed. By week 2, clinical (exudate quantity, erythema, stenosis, excoriation, and odor) and discomfort (pain, ear scratching, and head shaking) scores were significantly decreased (P < .0001 for all) and no microbial overgrowth could be detected in 25 (64.1%) and 32 (68.1%) ears treated with Epiotic and Epiotic Advanced, respectively. The new pH-balanced, propylene glycol-free test ear cleanser, which incorporates microbial adhesin-blocking carbohydrates, proved as effective as the reference acidic formula.


Subject(s)
Anti-Infective Agents, Local/administration & dosage , Dog Diseases/drug therapy , Otitis Externa/veterinary , Administration, Topical , Animals , Bacterial Adhesion , Dog Diseases/microbiology , Dog Diseases/pathology , Dogs , Drug Therapy, Combination , Ear Canal , Female , Male , Otitis Externa/drug therapy , Treatment Outcome
5.
Toxicol Lett ; 120(1-3): 151-60, 2001 Mar 31.
Article in English | MEDLINE | ID: mdl-11323172

ABSTRACT

The role of epigenetic modification of gene expression is becoming increasingly important in how we understand the loss of tumour suppressor gene function in a variety of tumours and tumour predisposing syndromes. This review explores the importance of epimutation in Beckwith-Wiedemann syndrome and Wilms' tumour and focuses on genomic methylation in both imprinted and non-imprinted genes as a key mechanism in the development of cancer.


Subject(s)
Genomic Imprinting , Neoplasms/genetics , Aging , Beckwith-Wiedemann Syndrome/genetics , DNA Methylation , Gene Silencing , Genes, Tumor Suppressor , Humans , Insulin-Like Growth Factor II/genetics , Multigene Family
7.
AANA J ; 68(3): 259-64, 2000 Jun.
Article in English | MEDLINE | ID: mdl-11132014

ABSTRACT

Xenon is a naturally occurring, gaseous element that comprises 0.000008% of air, or 0.05 parts per million. It was discovered by Ramsey and Travers in 1898. Xenon is found on the Periodic Table in group 0, which is the group commonly referred to as the noble or inert gases. It is obtained by fractionally distilling liquefied air. Xenon has been studied sporadically within the discipline of anesthesia as a replacement for nitrous oxide. Because it is a naturally occurring element, xenon is not a pollutant. It is not an occupationally hazardous gas. It is neither teratogenic nor fetotoxic, as is nitrous oxide; it does not contribute to the depletion of stratospheric ozone, as do chlorofluorocarbons and nitrous oxide. Xenon does not contribute to global warming and the greenhouse effect, as does nitrous oxide. Xenon provides excellent anesthesia and analgesia at its minimum alveolar concentration, 71%, as well as excellent analgesia at "subanesthetic" concentrations. Xenon also provides excellent cardiovascular and hemodynamic stability and offers both rapid induction and emergence. Because of the relatively high cost of xenon, a low-flow, closed-system technique is needed to be most cost effective.


Subject(s)
Anesthesia, Inhalation/trends , Anesthetics, Inhalation/therapeutic use , Xenon/therapeutic use , Humans , Nurse Anesthetists
9.
AANA J ; 67(1): 59-66, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10488278

ABSTRACT

Narcolepsy is a derangement of the normal sleep-wakefulness rhythms. Originally, narcolepsy was thought to be a form of epilepsy; however, with the development and subsequent refinement of the electroencephalograph, this notion is no longer accepted. The disorder is characterized by inappropriate intrusions of rapid eye movement sleep into the wakeful state and multiple disruptions of the sleep cycles. Narcolepsy usually has its onset anytime between the ages of 10 years and 50 years, with the greatest majority of patients first reporting noticeable symptoms between the ages of 15 and 35 years. Patients with narcolepsy may exhibit excessive daytime sleepiness, cataplexy, hypnogogic and/or hypnopompic hallucinations, and sleep paralysis. The cause of narcolepsy is presently unknown. Recent research has identified a possible genetic contribution via chromosome 6, but some form of environmental influence appears to be necessary for the disorder to be manifested. There is no cure for narcolepsy; however, symptomatic relief may be achieved through a trial-and-error combination of amphetamines and tricyclic antidepressants. The nature of narcolepsy often forces the individual to undergo some rather dramatic lifestyle changes and can lead to the development of other associate disorders, such as depression and obesity.


Subject(s)
Anesthesia/adverse effects , Anesthesia/methods , Narcolepsy/complications , Anesthesia/nursing , Diagnosis, Differential , Drug Interactions , Humans , Information Services , Internet , Narcolepsy/diagnosis , Narcolepsy/drug therapy , Narcolepsy/physiopathology , Nurse Anesthetists , Sleep Stages
10.
J Med Genet ; 36(7): 518-23, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10424811

ABSTRACT

Beckwith-Wiedemann syndrome (BWS) is a human imprinting disorder with a variable phenotype. The major features are anterior abdominal wall defects including exomphalos (omphalocele), pre- and postnatal overgrowth, and macroglossia. Additional less frequent complications include specific developmental defects and a predisposition to embryonal tumours. BWS is genetically heterogeneous and epigenetic changes in the IGF2/H19 genes resulting in overexpression of IGF2 have been implicated in many cases. Recently germline mutations in the cyclin dependent kinase inhibitor gene CDKN1C (p57KIP2) have been reported in a variable minority of BWS patients. We have investigated a large series of familial and sporadic BWS patients for evidence of CDKN1C mutations by direct gene sequencing. A total of 70 patients with classical BWS were investigated; 54 were sporadic with no evidence of UPD and 16 were familial from seven kindreds. Novel germline CDKN1C mutations were identified in five probands, 3/7 (43%) familial cases and 2/54 (4%) sporadic cases. There was no association between germline CDKN1C mutations and IGF2 or H19 epigenotype abnormalities. The clinical phenotype of 13 BWS patients with germline CDKN1C mutations was compared to that of BWS patients with other defined types of molecular pathology. This showed a significantly higher frequency of exomphalos in the CDKN1C mutation cases (11/13) than in patients with an imprinting centre defect (associated with biallelic IGF2 expression and H19 silencing) (0/5, p<0.005) or patients with uniparental disomy (0/9, p<0.005). However, there was no association between germline CDKN1C mutations and risk of embryonal tumours. No CDKN1C mutations were identified in six non-BWS patients with overgrowth and Wilms tumour. These findings (1) show that germline CDKN1C mutations are a frequent cause of familial but not sporadic BWS, (2) suggest that CDKN1C mutations probably cause BWS independently of changes in IGF2/H19 imprinting, (3) provide evidence that aspects of the BWS phenotype may be correlated with the involvement of specific imprinted genes, and (4) link genotype-phenotype relationships in BWS and the results of murine experimental models of BWS.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Germ-Line Mutation , Nuclear Proteins/genetics , Cyclin-Dependent Kinase Inhibitor p57 , Genomic Imprinting , Genotype , Humans , Phenotype , Sequence Analysis, DNA
11.
Proc Natl Acad Sci U S A ; 96(14): 8064-9, 1999 Jul 06.
Article in English | MEDLINE | ID: mdl-10393948

ABSTRACT

Loss of imprinting at IGF2, generally through an H19-independent mechanism, is associated with a large percentage of patients with the overgrowth and cancer predisposition condition Beckwith-Wiedemann syndrome (BWS). Imprinting control elements are proposed to exist within the KvLQT1 locus, because multiple BWS-associated chromosome rearrangements disrupt this gene. We have identified an evolutionarily conserved, maternally methylated CpG island (KvDMR1) in an intron of the KvLQT1 gene. Among 12 cases of BWS with normal H19 methylation, 5 showed demethylation of KvDMR1 in fibroblast or lymphocyte DNA; whereas, in 4 cases of BWS with H19 hypermethylation, methylation at KvDMRl was normal. Thus, inactivation of H19 and hypomethylation at KvDMR1 (or an associated phenomenon) represent distinct epigenetic anomalies associated with biallelic expression of IGF2. Reverse transcription-PCR analysis of the human and syntenic mouse loci identified the presence of a KvDMR1-associated RNA transcribed exclusively from the paternal allele and in the opposite orientation with respect to the maternally expressed KvLQT1 gene. We propose that KvDMR1 and/or its associated antisense RNA (KvLQT1-AS) represents an additional imprinting control element or center in the human 11p15.5 and mouse distal 7 imprinted domains.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Chromosomes, Human, Pair 15 , DNA, Antisense/genetics , Dinucleoside Phosphates/analysis , Genomic Imprinting , Membrane Proteins , Potassium Channels, Voltage-Gated , Potassium Channels/genetics , Transcription, Genetic , Animals , Base Sequence , Cell Line , Chromosome Mapping , DNA/genetics , DNA Methylation , Female , Humans , KCNQ Potassium Channels , KCNQ1 Potassium Channel , Long QT Syndrome/genetics , Lymphocytes/physiology , Male , Mice , Molecular Sequence Data , Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction
12.
AANA J ; 67(5): 469-73, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10876439

ABSTRACT

Pulmonary edema is a generalized descriptive term for the accumulation of fluid within the interstitium and/or the alveolar spaces of the lungs. This accumulation of fluid has a cause that may be termed cardiogenic or noncardiogenic. Pulmonary edema of cardiogenic origin is usually due to failure of the left side of the heart, but it also can be attributed to the right side of the heart. Noncardiogenic pulmonary edema (NCPE) usually is attributable to certain lung injuries or disease states, but it also can be neurogenic in origin. Some occurrences of NCPE can be traced directly to the administration of anesthesia. For example, NCPE can result from upper airway obstruction or the administration of naloxone.


Subject(s)
Airway Obstruction/complications , Anesthesia/adverse effects , Laryngismus/complications , Naloxone/adverse effects , Narcotic Antagonists/adverse effects , Pulmonary Edema/etiology , Capillary Permeability , Capillary Resistance , Humans , Osmotic Pressure , Pressure , Pulmonary Edema/diagnosis , Pulmonary Edema/physiopathology , Pulmonary Edema/therapy , Risk Factors
13.
Mol Pathol ; 51(4): 185-90, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9893743

ABSTRACT

Genomic imprinting is the phenomenon by which individual alleles of certain genes are expressed differentially according to their parent of origin. The alleles appear to be differentially marked during gametogenesis or during the early part of development. This mark is heritable but reversible from generation to generation, implying a stable epigenetic modification. Approximately 25 imprinted genes have been identified to date, and dysregulation of a number of these has been implicated in tumour development. The normal physiological role of many imprinted genes is in the control of cell proliferation and fetal growth, indicating potential mechanisms of action in tumour formation. Both dominant and recessive modes of action have been postulated for the role of imprinted genes in neoplasia, as a result of effective gene dosage alterations by epigenetic modification of the normal pattern of allele specific transcription. The aim of this review is to assess the importance of imprinted genes in generating tumours and to discuss the implications for novel mechanisms of transforming mutation.


Subject(s)
Genomic Imprinting , Neoplasms/genetics , Chromosomes, Human, Pair 11 , Genes, Tumor Suppressor , Humans , Somatomedins/physiology
14.
Hum Mol Genet ; 6(9): 1543-8, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9285792

ABSTRACT

Genomic imprinting is a novel form of control of gene expression in which the transcription of each allele of an imprinted gene is dependent on the sex of the gamete from which it was derived; to date > 15 genes have been demonstrated to show imprinting. The maintenance of a normal imprinting pattern in many loci has been shown to be essential for normal development and adult life. Many tumours, and some developmental disorders, exhibit loss of imprinting (LOI) in key genes such as insulin-like growth factor 2 (IGF2) which often results in hyperplasia and is associated with cancer. The mechanism by which the genomic imprint is first established, then maintained, is not understood. However, in the case of IGF2, the expression of a neighbouring gene, H19, has been suggested to influence its transcription by competition for a common enhancer, thereby generating a mutually exclusive and allele-specific pattern of gene expression. Associated changes in CpG methylation in discrete areas of both genes have been implicated in maintenance of the imprint. We have examined the allele-specific expression of IGF2 and H19 in fibroblasts derived from patients with sporadic Beckwith-Wiedemann syndrome (BWS), a fetal overgrowth syndrome associated with an imprinted locus on 11p15.5. We report that the majority of karyotypically normal patients show LOI of IGF2 with biallelic expression. In a proportion of these patients, loss of IGF2 imprinting was associated with complete suppression of H19 expression, as predicted by the enhancer competition model. However, in a significant number of cases, IGF2 showed biallelic expression even though H19 expression and methylation status were normal. This indicates that there must be an alternative H19-independent pathway by which allele-specific IGF2 expression is established or maintained.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Fibroblasts/metabolism , Genomic Imprinting/genetics , Insulin-Like Growth Factor II/genetics , Muscle Proteins/genetics , RNA, Untranslated , Cell Culture Techniques , DNA Methylation , Gene Expression , Humans , RNA, Long Noncoding
15.
J Med Genet ; 34(5): 353-9, 1997 May.
Article in English | MEDLINE | ID: mdl-9152830

ABSTRACT

Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth syndrome associated with a characteristic pattern of visceromegaly and predisposition to childhood tumours. BWS is a genetically heterogeneous disorder; most cases are sporadic but approximately 15% are familial and a small number of BWS patients have cytogenetic abnormalities involving chromosome 11p15. Genomic imprinting effects have been implicated in familial and non-familial BWS. We have investigated the molecular pathology of 106 sporadic BWS cases; 17% (14/83) of informative cases had uniparental disomy (UPD) for chromosome 11p15.5. In each case UPD appeared to result from a postzygotic event resulting in mosaicism for segmental paternal isodisomy. The critical region for isodisomy was refined to a 25 cM interval between D11S861 and D11S2071 which contained the IGF2, H19, and p57(KIP2) genes. In three cases isodisomy for 11q markers was detected but this did not extend further than 11q13-q21 suggesting that complete chromosome 11 disomy may not produce a BWS phenotype. The allele specific methylation status of the H19 gene was investigated in 80 sporadic BWS cases. All 13 cases with UPD tested displayed hypermethylation consistent with an excess of paternal H19 alleles. In addition, five of 63 (8%) cases with normal biparental inheritance had H19 hypermethylation consistent with an "imprinting centre" mutation (ICM) or "imprinting error" (IE) lesion. The phenotype of patients with putative ICM/IE mutations was variable and overlapped with that of non-UPD sporadic BWS cases with normal H19 methylation. However, exomphalos was significantly (p < 0.05) more common in the latter group. These findings may indicate differential effects on the expression of imprinted genes in chromosome 11p15 according to the precise molecular pathology. Analysis of H19 methylation is useful for the diagnosis of both UPD or altered imprinting in BWS and shows that a variety of molecular mechanisms may cause relaxation of IGF2 imprinting in BWS.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Genomic Imprinting/genetics , Muscle Proteins/metabolism , RNA, Untranslated , Aneuploidy , Beckwith-Wiedemann Syndrome/classification , Beckwith-Wiedemann Syndrome/diagnosis , Chromosomes, Human, Pair 11 , DNA Methylation , Female , Humans , Male , Muscle Proteins/genetics , Phenotype , RNA, Long Noncoding
16.
J Small Anim Pract ; 38(4): 152-8, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9127283

ABSTRACT

Data are presented from 15 dogs with aural haematoma. The series included six Labrador retrievers and four golden retrievers and the mean age was 8.0 +/- 3.02 years. Five dogs had evidence of pruritic skin disease and five further cases had other concurrent disease. Haematology and serum biochemistry were normal in 12 and 13 of the 15 dogs, respectively. All dogs were Coombs' negative and serum antinuclear antibody had negative or low titres in all the 11 cases tested. Histopathological examination of biopsies from the affected ears revealed variable degrees of erosion of auricular cartilage with fibrovascular granulation tissue filling the cartilage defects. There was minimal perichondral inflammation. The biopsies were studied by immunohistochemistry for deposition of immunoglobulin G (IgG), immunoglobulin M (IgM) and complement C3. In one dog there was basement membrane zone deposition of IgG and in another there was focal interepithelial deposition of both IgG and IgM. The findings of this study do not support an autoimmune pathogenesis for canine aural haematoma, but suggest that an early immunological event may underlie the observed cartilage erosion.


Subject(s)
Dog Diseases/etiology , Dog Diseases/immunology , Ear Diseases/veterinary , Ear, External/pathology , Hematoma/veterinary , Animals , Antibodies, Antinuclear/analysis , Autoimmune Diseases/etiology , Autoimmune Diseases/immunology , Autoimmune Diseases/veterinary , Biopsy/methods , Biopsy/veterinary , Complement C3c/analysis , Coombs Test/methods , Coombs Test/veterinary , Dog Diseases/pathology , Dogs , Ear Cartilage/chemistry , Ear Cartilage/immunology , Ear Cartilage/pathology , Ear Diseases/etiology , Ear Diseases/immunology , Ear, External/chemistry , Ear, External/immunology , Epidermis/chemistry , Epidermis/immunology , Epidermis/pathology , Female , Fluorescent Antibody Technique/methods , Fluorescent Antibody Technique/veterinary , Hematoma/etiology , Hematoma/immunology , Immunoglobulin G/analysis , Immunoglobulin M/analysis , Male
17.
J Med Genet ; 33(12): 981-5, 1996 Dec.
Article in English | MEDLINE | ID: mdl-9004127

ABSTRACT

Hereditary non-polyposis colorectal cancer syndrome (HNPCC) is often considered to be the most common form of inherited colorectal cancer, although its precise incidence is unknown. The clinical diagnosis of HNPCC relies on a combination of family history and young age of onset of colorectal cancer, but as many familial aggregations of colorectal cancer do not fulfil the strict diagnostic criteria, HNPCC might be underdiagnosed. The majority of HNPCC families have germline mutations in mismatch repair (MMR) genes, such as MSH2 or MLH1, so that HNPCC cancers characteristically exhibit DNA replication errors (RERs) at microsatellite loci. Although an RER positive phenotype in tumours can also result from somatic mutations in an MMR gene, the prevalence of RER + tumours should provide a maximum estimate of the incidence of germline MMR gene mutations in patients with early onset and familial colorectal cancer. We investigated colorectal cancers for RERs from (1) a population based study of 33 patients with colorectal cancer aged 45 years or less, (2) 65 kindreds with familial colorectal cancer which only partially fulfilled the criteria for the diagnosis of HNPCC, and (3) 18 cancers from 12 HNPCC kindreds. Seven of 33 patients (21%) with colorectal cancer aged 45 years or less had an RER + cancer, with only two of these having a clear family history of HNPCC. A greater proportion of RER + tumours (5/7) occurred proximal to the splenic flexure than RER - tumours (4/26; chi2 = 6.14, p < 0.025). RERs were detected in all 18 cancers from HNPCC patients but in only six of 65 non-HNPCC familial colorectal cancer kindreds (9%; chi2 = 52.2, p < 0.0005). These findings suggest that most cancers in patients diagnosed at 45 years of age or less and familial aggregations of colorectal cancer which do not fulfil HNPCC diagnostic criteria do not have germline mutations in MSH2 and MLH1. Hence population screening for germline mutations in these genes is unlikely to be an efficient strategy for identifying people at high risk of developing colorectal cancer.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Fungal Proteins , Microsatellite Repeats , Adult , Age of Onset , Colorectal Neoplasms, Hereditary Nonpolyposis/epidemiology , DNA Repair/genetics , DNA Replication , DNA-Binding Proteins/genetics , Female , Germ-Line Mutation , Humans , Male , Middle Aged , MutS Homolog 2 Protein , Pedigree , United Kingdom/epidemiology
18.
AANA J ; 64(5): 480-4, 1996 Oct.
Article in English | MEDLINE | ID: mdl-9124031

ABSTRACT

A 95-kg, 34-year-old male presented for exploration of the thoracic aorta to resect an apparent sarcoma. A significant complication for this surgery is that of paraplegia and/or paraparesis. Continuous monitoring of cerebrospinal fluid pressure and drainage to maintain the pressure at 10 mmHg or less has been advocated to preserve nominal spinal cord perfusion pressure. However, this intervention alone has not demonstrated any greater efficacy in the prevention of paraplegia or paraparesis than no such intervention at all. Naloxone, the narcotic antagonist, has been studied extensively in relation to human paralysis and endogenous opioid actions. More recently, investigators have proposed combining a naloxone infusion with cerebrospinal fluid monitoring and drainage to attempt to prevent the occurrence of paraplegia and/or paraparesis in patients undergoing thoracic or thoracoabdominal aortic surgery. These interventions would seem at least theoretically appropriate to maximize spinal cord perfusion pressure and preserve spinal cord function. However, the extent of investigations is currently limited and the results somewhat controversial.


Subject(s)
Aorta, Thoracic , Naloxone/administration & dosage , Narcotic Antagonists/administration & dosage , Sarcoma/surgery , Vascular Neoplasms/surgery , Adult , Cerebrospinal Fluid Pressure , Humans , Intraoperative Complications/prevention & control , Male , Monitoring, Intraoperative , Paraplegia/prevention & control
20.
Clin Genet ; 48(6): 299-303, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8835324

ABSTRACT

Familial adenomatous polyposis coli is caused by constitutional mutations in the APC gene. The hallmark of familial adenomatous polyposis coli is the presence of numerous (> 100) colorectal polyps, but mutations in the 5' end of the APC gene have been associated with familial colorectal cancer without florid polyposis. Although familial adenomatous polyposis coli accounts for only a minority of familial colorectal cancer cases, we hypothesised that APC mutations which were not associated with florid polyposis might make a significant contribution to nonpolyposis familial colorectal cancer. To investigate this possibility, we analysed 40 unrelated patients with familial colorectal cancer without classical familial adenomatous polyposis coli for mutations in exons 1 to 6 (codons 1 to 243) of the APC gene. No mutations were detected, but a C-->T polymorphism at nucleotide 333 (Arg-->Trp at codon 99) was identified. No 5' APC mutations were detected in two patients with desmoid tumours and a family history of colorectal cancer and polyps. We conclude that mutations in exons 1 to 6 of the APC gene are infrequent in patients with familial colorectal cancer who do not have many colorectal polyps.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Fibromatosis, Aggressive/genetics , Genes, APC , Adult , Aged , Base Sequence , DNA Primers , Exons , Female , Humans , Male , Middle Aged , Molecular Biology , Molecular Sequence Data , Mutation
SELECTION OF CITATIONS
SEARCH DETAIL
...